Our mission is to develop safe, cost-effective gene therapies to address serious unmet treatment needs in today’s largest patient populations.
Our Platform
We aim to redefine genetic medicine by enabling precise modulation of disease biology — safely, flexibly, and at scale. Our proprietary gene therapies deliver plasmids that can selectively upregulate or downregulate the expression of a chosen disease-driving target. Our platform enables both viral and non-viral modes of delivery. We have demonstrated durable results using AAV6 delivery, with 12 to 15 months of therapeutic effects from a single intravenous dose. Our technology can also incorporate a “kill switch” for additional safety.
Our Indications
We’ve developed a library of more than 90 proprietary gene therapy vectors targeting a broad range of therapeutic areas where safer, more precise gene therapies are urgently needed. These include autoimmune, neurological, metabolic, and infectious diseases, and oncology.
Our Development
We have conducted extensive preclinical studies of our platform. Our data demonstrates robust safety and efficacy performance, in both human cells and animal models, and across multiple modes of administration. We are now preparing to enter clinical stage development.
In tandem with our clinical work, we are refining our proprietary manufacturing process, designed to reduce our cost of goods at commercial scale to below that of currently approved gene therapies.
The Company
Wyvern Pharmaceuticals Inc. is a privately held gene therapy company headquartered in Calgary, Canada. Our executive team brings together decades of experience in drug development and taking new therapies to market. Together, we aim to deliver meaningful quality of life and lifespan extension benefits to patient populations with serious unmet treatment needs.
Our proprietary gene therapy platform is designed to safely and effectively treat serious illnesses, including autoimmune, metabolic and neurological conditions, cancer, and infectious diseases.
For more information